Welcome to our dedicated page for ZEO ScientifiX SEC filings (Ticker: zeox), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ZEO ScientifiX's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ZEO ScientifiX's regulatory disclosures and financial reporting.
Zeo ScientifiX, Inc. announced a leadership change, making Ian T. Bothwell the company’s full-time Chief Executive Officer effective December 24, 2025. He had been serving as Interim Chief Executive Officer while also holding the role of Chief Financial Officer, and will continue in the dual position of Chief Executive Officer and Chief Financial Officer. This move formalizes the company’s executive leadership structure by confirming Bothwell as permanent CEO.
Zeo ScientifiX, Inc. reported that, effective November 30, 2025, it terminated the employment of Ron Borsheim as its Chief Sales Officer – Aesthetics. The company identifies itself as a Nevada corporation with principal offices in Davie, Florida, and it currently has no securities listed on a national securities exchange. The report is signed by Interim Chief Executive Officer and Chief Financial Officer Ian T. Bothwell, indicating executive-level oversight of this leadership change.
Zeo ScientifiX, Inc. filed an 8-K reporting that on October 23, 2025 it issued a press release stating the company is prepared to capitalize on the potentially rapid expansion of Florida’s regenerative medicine market following enactment of the new state stem cell law, SB 1768, effective July 1, 2025.
The press release is furnished as Exhibit 99.1 and incorporated by reference.
Zeo ScientifiX, Inc. (ZEOX) filed a Form 10-Q showing constrained liquidity and a continuing operations focus on clinical and commercial support. The company reported $4,706,000 for the nine months ended July 31, 2025, used $335,000 of cash in operating activities in that period, and had a stockholders’ deficit of $2,314,000 at July 31, 2025. The balance sheet shows multiple finance leases entered into in June 2025 for equipment (one with 60 monthly payments of $1,600 at 2.7% and one with 36 monthly payments of $500 at 8.0%), and a recent asset purchase of BIO assets with a $200,000 purchase price largely allocated to inventory.
Capital structure items include $725,000 of convertible debt (convertible into up to 120,834 shares), significant stock-based compensation and warrant grants (including grants with a $1,428,000 fair value for warrants), and 263,333 unvested restricted shares (178,333 unissued). Revenue concentration is notable, with single customers representing double-digit percentages of revenues in multiple periods. The filing discloses commissions earned under a Sales Agreement ($62,000 for nine months ended July 31, 2025) and related-party product sales to an MSO tied to the Chief Medical Officer.